Pilot Study of Application of Combined Transbronchial and Intravenous Ultraviolet C (UVC) and Laser Beam Application for the Treatment of Critical COVID-19 Infection

Objective and background: Light-based antimicrobials, mainly ultraviolet C (UVC) laser light irradiation, have a potential to inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of our study was evaluate the effect transbronchial intravenous application UVC irradiation on treatment patients with COVID-19. Methods: clinical outcome six (age 42-69 years) COVID-19 infection who were directly applied (254 nm) transbronchially, plus green (630 red (535 lights blood circulation in addition standard pharmacotherapy (UVC group) prospectively evaluated comparison 50-69 treated only (standard group). Results: group had shorter stay intensive care unit (median length 1 vs. 8.5 days; p=0.015), more negative PCR results after (5/6 0/6 patients; p=0.003), higher discharge rate 3/6 patients), lower mortality (1/6 as compared group. Serum D-dimer level, which reached up 2500 ng/mL (six times baseline value) seven days group, much (1000 ng/mL). ferritin level 1.5 1.9-fold CRP 1.7-fold during ten No adverse effects been observed. Conclusions: Combined may improve cases.